Top

International Journal of Clinical Oncology

Published in:

01-10-2018 | Original Article

Genetic mutation analysis of the malignant transformation of sinonasal inverted papilloma by targeted amplicon sequencing

Authors: Shinichiro Yasukawa, Satoshi Kano, Hiromitsu Hatakeyama, Yuji Nakamaru, Dai Takagi, Takatsugu Mizumachi, Masanobu Suzuki, Takayoshi Suzuki, Akira Nakazono, Shinya Tanaka, Hiroshi Nishihara, Akihiro Homma

Published in: International Journal of Clinical Oncology | Issue 5/2018

Abstract

Background

The mechanism underlying the malignant transformation of inverted papilloma (IP) has not yet been elucidated.

Methods

To clarify the genes responsible for the malignant transformation, we analyzed 10 cases of IP, 8 of IP with dysplasia, and 11 of squamous cell carcinoma (SCC) by targeted amplicon sequencing.

Results

The number of mutant genes increased in the order of IP < dysplasia < SCC. Significant differences were observed in the mutation rates of three genes (KRAS, APC and STK11) in particular. TP53 was altered frequently in each group and might be involved in malignant transformation based on to the site of the mutation. A comparison of the genetic variants by region of IP tissue among patients with IP alone, and those with dysplasia or SCC revealed significant differences in the mutation rate of the KRAS gene.

Conclusion

Identification of genetic mutations in KRAS is effective for predicting the malignant transformation of IP.

Batsakis JG, Suarez P (2001) Schneiderian papillomas and carcinomas: a review. Adv Anat Pathol 8:53–64CrossRefPubMed

Buchwald C, Franzmann MB, Tos M (1995) Sinonasal papillomas: a report of 82 cases in Copenhagen County, including a longitudinal epidemiological and clinical study. Laryngoscope 105:72–79CrossRefPubMed

Re M, Zizzi A, Ferrante L et al (2014) p63 and Ki-67 immunostainings in laryngeal squamous cell carcinoma are related to survival. Eur Arch Otorhinolaryngol 271:1641–1651CrossRefPubMed

Lawson W, Kaufman MR, Biller HF (2003) Treatment outcomes in the management of inverted papilloma: an analysis of 160 cases. Laryngoscope 113:1548–1556CrossRefPubMed

Schlosser RJ, Mason JC, Gross CW (2001) Aggressive endoscopic resection of inverted papilloma: an update. Otolaryngol Head Neck Surg 25:49–53CrossRef

Sanderson RJ, Knegt PK (1999) Management of inverted papilloma via Denker’s approach. Clin Otolaryngol 24:69–71CrossRefPubMed

Deitmer T, Wiener C (1996) Is there an occupational etiology of inverted papilloma of the nose and sinuses? Acta Otolaryngol 116:762–765CrossRefPubMed

Davey JW, Hohenlohe PA, Etter PD et al (2011) Genome-wide genetic marker discovery and genotyping using next-generation sequencing. Nat Rev Genet 12:499–510CrossRefPubMed

Coco S, Truini A, Vanni I et al (2015) Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine. Curr Drug Targets 16:47–59CrossRefPubMed

10.

The Cancer Genome Atlas Network (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576–582CrossRefPubMedCentral

11.

Lee GH, Yoon YH, Kim YM et al (2012) Pattern of expression of cyclooxygenase-2 in malignant transformation of sinonasal inverted papilloma. Am J Otolaryngol 33(5):585–589CrossRefPubMed

12.

Yamashita Y, Hasegawa M, Deng Z et al (2015) Human papillomavirus infection and immunohistochemical expression of cell cycle proteins pRb, p53, and p16(INK4a) in sinonasal diseases. Infect Agent Cancer 10:23CrossRefPubMedPubMedCentral

13.

Zhao RW, Guo ZQ, Zhang RX (2016) Human papillomavirus infection and the malignant transformation of sinonasal inverted papilloma: a meta-analysis. J Clin Virol 79:36–43CrossRefPubMed

14.

Huang CC, Lee TJ, Chang PH et al (2010) Desmoglein 3 is overexpressed in inverted papilloma and squamous cell carcinoma of sinonasal cavity. Laryngoscope 120:26–29CrossRefPubMed

15.

Koo BS, Jung BJ, Kim SG, et al. (2011) Altered expression of E-cadherin and β-catenin in malignant transformation of sinonasal inverted papillomas. Rhinology 49:479–485PubMed

16.

Lin GC, Scheel A, Akkina S et al (2013) Epidermal growth factor receptor, p16, cyclin D1, and p53 staining patterns for inverted papilloma. Int Forum Allergy Rhinol 3:885–889CrossRefPubMedPubMedCentral

17.

Oncel S, Cosgul T, Calli A et al (2011) Evaluation of p53, p63, p21, p27, ki-67 in paranasal sinus squamous cell carcinoma and inverted papilloma. Indian J Otolaryngol Head Neck Surg 63:172–177CrossRefPubMedPubMedCentral

18.

Tsou YA, Huang HJ, Wang TC et al (2014) Evaluation of correlation of cell cycle proteins and Ki-67 interaction in paranasal sinus inverted papilloma prognosis and squamous cell carcinoma transformation. Biomed Res Int 2014:634945CrossRefPubMedPubMedCentral

19.

Wu HH, Zafar S, Huan Y et al (2009) Fascin over expression is associated with dysplastic changes in sinonasal inverted papillomas: a study of 47 cases. Head Neck Pathol 3:212–216CrossRefPubMedPubMedCentral

20.

Udager AM, Rolland DCM, McHugh JB et al (2015) High-frequency targetable EGFR mutations in sinonasal squamous cell carcinomas arising from inverted sinonasal papilloma. Cancer Res 75:2600–2606CrossRefPubMedPubMedCentral

21.

Udager AM, McHugh JB, Betz BL et al (2016) Activating KRAS mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma. J Pathol 239:394–398CrossRefPubMed

Title: Genetic mutation analysis of the malignant transformation of sinonasal inverted papilloma by targeted amplicon sequencing
Authors: Shinichiro Yasukawa
Satoshi Kano
Hiromitsu Hatakeyama
Yuji Nakamaru
Dai Takagi
Takatsugu Mizumachi
Masanobu Suzuki
Takayoshi Suzuki
Akira Nakazono
Shinya Tanaka
Hiroshi Nishihara
Akihiro Homma
Publication date: 01-10-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 5/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1296-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2018

Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma

Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma

Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy

A prospective feasibility study applying the ACOSOG Z0011 criteria to Japanese patients with early breast cancer undergoing breast-conserving surgery

Analysis of unexplained carcinoembryonic antigen elevation after curative treatment of locally advanced rectal cancer

Early intervention using high-precision radiotherapy preserved visual function for five consecutive patients with optic nerve sheath meningioma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer